A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial

被引：0

作者：

Naoto Takahashi

Mitsuro Kanda

Takaki Yoshikawa

Nobuhiro Takiguchi

Kazumasa Fujitani

Katsufumi Miyamoto

Yuichi Ito

Osamu Takayama

Motohiro Imano

Norio Mitsumori

Junichi Sakamoto

Satoshi Morita

Yasuhiro Kodera

机构：

[1] Kashiwa Hospital,Department of Surgery, Jikei University School of Medicine

[2] Nagoya University Graduate School of Medicine,Department of Gastroenterological Surgery (Surgery II)

[3] Kanagawa Cancer Center,Department of Gastrointestinal Surgery

[4] Chiba Cancer Center,Division of Gastroenterological Surgery

[5] Osaka Prefectural General Medical Center,Department of Surgery

[6] Hyogo Prefectural Awaji Medical Center,Department of Surgery

[7] Aichi Cancer Center Hospital,Department of Gastroenterological Surgery

[8] Itami City Hospital,Department of Surgery

[9] Kinki University,Department of Surgery, Faculty of Medicine

[10] Jikei University School of Medicine,Department of Surgery

[11] Tokai Central Hospital,Department of Biomedical Statistics and Bioinformatics

[12] Kyoto University Graduate School of Medicine,undefined

来源：

Gastric Cancer | 2018年 / 21卷

关键词：

Gastric cancer; Intraperitoneal administration; Paclitaxel; Peritoneal metastasis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1014 / 1023

页数：9

共 43 条

[21] A multicenter, randomized, phase 3 trial of a novel autologous therapeutic vaccine (vitespen) vs. observation as adjuvant therapy in patients at high risk of recurrence after nephrectomy for renal cell carcinoma
Wood, Christopher
Escudier, Bernard
Lacombe, Louis
Hoos, Axel
Gupta, Renu
Flanigan, Robert
Figlin, Robert
Srivastava, Pramod
JOURNAL OF IMMUNOTHERAPY, 2006, 29 (06) : 658 - 658
[22] A multicenter, randomized, phase 3 trial of a novel autologous therapeutic vaccine (vitespen) vs. observation as adjuvant therapy in patients at high risk of recurrence after nephrectomy for renal cell carcinoma
Wood, Christopher G.
Escudier, Bernard
Lacombe, Louis
Hoos, Axel
Gupta, Renu
Toofilovici, Florentina
Flanigan, Robert C.
Figlin, Robert A.
Srivastava, Pramod
JOURNAL OF UROLOGY, 2007, 177 (04): : 212 - 212
[23] Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
Concin, Nicole
Braicu, Ioana
Combe, Pierre
Ray-Coquard, Isabelle Laure
Joly, Florence
Harter, Philipp
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[24] Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis
Martin, Miguel
Chacon, Jose I.
Anton, Antonio
Plazaola, Arrate
Garcia-Martinez, Elena
Segui, Miguel A.
Sanchez-Rovira, Pedro
Palacios, Jose
Calvo, Lourdes
Esteban, Carmen
Espinosa, Enrique
Barnadas, Agusti
Batista, Norberto
Guerrero, Angel
Munoz, Montserrat
Romio, Estefania
Rodriguez-Martin, Cesar
Caballero, Rosalia
Casas, Maria I.
Rojo, Federico
Carrasco, Eva
Antolin, Silvia
ONCOLOGIST, 2017, 22 (11): : 1301 - 1308
[25] A phase III randomized, open-label multicenter trial to evaluate the benefit of leuprorelin acetate for 24 months after radical prostatectomy in patients with high risk of recurrence (AFU-GETUG 20/0310)
Rozet, Francois
Habibian, Muriel
Berille, Jocelyne
Roca, Lise
Salomon, Laurent
Soulie, Michel
Culine, Stephane
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
[26] FINAL RESULTS OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP PHASE III TRIAL (HE10/00) EXPLORING THE EFFICACY OF POSTOPERATIVE DOSE-DENSE SEQUENTIAL CHEMOTHERAPY WITH EPIRUBICIN, PACLITAXEL AND CMF IN HIGH RISK BREAST CANCER PATIENTS
Gogas, H.
Dafni, U.
Dimopoulos, M. A.
Koutras, A. K.
Pisanidis, N.
Bafaloukos, D.
Skarlos, D.
Pavlidis, N.
Papakostas, P.
Fountzilas, G.
ANNALS OF ONCOLOGY, 2010, 21 : 78 - 78
[27] Update results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of recurrence after surgery-A single-arm, multicenter, phase II clinical trial.
Wu, Zheng
Wang, Zheng
Zhang, Lei
Song, Xiaojing
Du, Xilin
Tan, Kai
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16120 - E16120
[28] Final results on efficacy and patient reported outcomes (PRO) of a randomized phase II trial investigating nivolumab switch-maintenance after TKI induction in metastatic clear cell renal cell carcinoma (mRCC) patients (NIVOSWITCH)
Darr, C.
Zschaebitz, S.
Ivanyi, P.
Wirth, M.
Staib, P.
Schostak, M.
Mueller, L.
Metz, M.
Bergmann, L.
Steiner, T.
Lorch, A.
Schuett, P.
Rafiyan, M-R.
Hellmis, E.
Hinke, A.
Maenz, M.
Meiler, J.
Kretz, T.
Floercken, A.
Gruenwald, V.
ANNALS OF ONCOLOGY, 2021, 32 : S700 - S700
[29] Final results on efficacy and patient reported outcomes (PRO) of a randomized phase II trial investigating nivolumab switch-maintenance after TKI induction in metastatic clear cell renal cell carcinoma (mRCC) patients (NIVOSWITCH)
Darr, Christopher
Zschaebitz, Stefanie
Ivanyi, Philipp
Wirth, Manfred
Staib, Peter
Schostak, Martin
Mueller, Lothar
Metz, Michael
Bergmann, Lothar
Steiner, Thomas
Lorch, Anja
Schuett, Philipp
Rafiyan, Mohammad-Reze
Hellmis, Eva
Hinke, Axel
Maenz, Martin
Meiler, Johannes
Kretz, Thomas
Floercken, Anne
Gruenwald, Viktor
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 100 - 100
[30] Updated results from ALTER-H004 trial: Anlotinib combined with TACE as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgery-A single arm, multi-center, phase II clinical trial
Wu, Zheng
Wang, Zheng
Zhang, Lei
Song, Xiaojing
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →